RESUMO
Fluvastatin sodium is the first wholly synthetic 3 hydroxy-3-methylglytary 1 coenzyme A reductase inhibitor. It reduces cholesterol synthesis, enhances low density lipoprotein catalysis and hepatocyte LDL receptor expression. To evaluate the efficacy, tolerability and safety of fluvastatin sodium 40 mg once a day, we studied 40 patients with type IIA dyslipidemia. We observed a statistically significant reduction in total cholesterol (20.7%, p < 0.01), low density lipoprotein cholesterol (29.5%, p < 0.01), triglycerides (10.56%, p N.S.), very low density lipoprotein cholesterol (10.56%, p N.S.), C-LDL:C-HDL (33.7%, p < 0.01) and an increase in high density lipoprotein cholesterol (2.8%) after 12 weeks of treatment. No patient reported side effects and no clinically significant modifications in safety parameters were observed during the study. We conclude that fluvastatin sodium 40 mg once daily is efficacious, safe and well tolerated in the treatment of type IIA primary dyslipidemia.
